Market Herald logo

Subscribe

Be the first with the news that moves the market
  • OncoSil Medical (OSL) treats its second patient in a locally advanced pancreatic cancer clinical trial
  • The treatment was undertaken in Madrid, where the volunteer underwent a successful resection of a pancreatic tumour using the OncoSil device
  • The news follows the company signing a commercial agreement with the hospital for the treatment of patients with locally advanced pancreatic cancer, worth €374,000 (A$554,800)
  • OncoSil’s sales team in Spain are continuing to work with other trained hospitals to facilitate further agreements
  • OncoSil is up 1.72 per cent, trading at 5.9 cents at 1:34 pm AEST

OncoSil Medical (OSL) has treated its second patient in a locally advanced pancreatic cancer trial.

The treatment was undertaken at The Hospital Universitario de Fuenlabrada in Madrid, Spain, where the patient underwent a successful resection of a LAPC tumour using the OncoSil device.

OncoSil is a targeted radioactive isotope which is implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound. The treatment is designed to deliver more concentrated and localised beta radiation compared to external beam radiation.

The news follows the company signing a commercial agreement with the hospital for the treatment of patients with locally advanced pancreatic cancer, worth €374,000 (A$554,800).

OncoSil’s CEO and Managing Director Nigel Lange said the company is encouraged by the resection undertaken on the patient who had received the OncoSil device.

“In the PanCO trial, 23.8 per cent of patients who were treated with the OncoSil device were successfully resected which has been demonstrated to improve patient outcomes from this insidious disease,” Nigel Lange said.

“We look forward to working with additional institutions in Spain and throughout Europe, in order to accelerate the use of the OncoSil device for the benefit of patients suffering from LAPC.”

OncoSil’s sales team in Spain are continuing to work with other trained hospitals to facilitate further agreements. This is hoped to enable greater patient access to the OncoSil device treatment in various regions throughout Spain.

OncoSil was up 1.72 per cent, trading at 5.9 cents at 1:34 pm AEST.

OSL by the numbers
More From The Market Herald
The Market Herald Video

" Woomera Mining (ASX:WML) appoints Jason Livingstone as new Managing Director

Mineral explorer Woomera Mining (ASX:WML) has appointed Jason Livingstone as its new Managing Director, effective from…
The Market Herald Video

" Security Matters (ASX:SMX) enters into $2m standby equity facility

Security Matters (ASX:SMX) has entered into a standby equity deed with Evolution Capital.
The Market Herald Video

" Ora Gold (ASX:OAU) obtains unsecured $500k loan facility

Ora Gold (ASX:OAU) has obtained an unsecured $500,000 loan facility from Ioma to assist with general…
Baby Bunting (ASX:BBN) - Chair and Non Executive Director, Melanie Wilson

" Baby Bunting (ASX:BBN) surpasses $500m sales for the first time

Baby goods retailer Baby Bunting (ASX:BBN) surpasses half a billion dollars in sales for the first…